A well-governed basket or umbrella trial requires four explicitly designed governance bodies: a Steering Committee with defined decision authority over major protocol changes, an IDMC chartered specifically for adaptive review (with at least one member experienced in adaptive designs), a Safety Review Committee for programs with complex AE profiles or materially different arm safety profiles, and a Central IRB operating under a master protocol. Based on Sitero’s operational experience with master protocol oncology trials, a central IRB is the operationally superior model because local IRB review creates parallel processes that cannot be synchronized across cohorts and “can significantly prolong the time to trial activation.” The most important design principle across all four bodies is documented decision authority — specifying what each body can decide independently, what requires escalation, and what the timeline expectation is for each decision type.
—
Why Does Governance Failure Cause Operational Delay in Basket and Umbrella Trials?
Basket and umbrella trials fail operationally for many reasons. Governance failure is among the most common — and the least discussed. When the decision-making structure for a multi-arm, multi-stakeholder trial is unclear, delays accumulate at every decision point: protocol amendments, arm expansions, arm closures, safety escalations, enrollment pauses. Each decision that should take days takes weeks.
Getting governance right is a protocol design and CRO scoping question, not an operational detail to be resolved after study startup.
—
What Governance Bodies Does a Basket or Umbrella Trial Require?
Steering Committee
Overall scientific and operational authority for the trial. Includes sponsor, principal investigator(s), and key functional leads. Responsible for major protocol decisions and final authority on adaptive changes. In multi-sponsor umbrella programs, the steering committee structure must explicitly address how competing sponsor interests are balanced — a governance gap that is easy to overlook when commercial negotiations are ongoing and harder to resolve once the trial is running.
Independent Data Monitoring Committee (IDMC)
Reviews unblinded interim data and makes recommendations on adaptations, arm closures, or safety-related trial modifications. Must include at least one member with specific adaptive trial experience, per ROBIN project recommendations (BMC Medicine, 2025). The IDMC charter must explicitly address how recommendations are communicated to the steering committee and implemented through operations — the communication protocol is as important as the statistical boundary.
Safety Review Committee
For trials with complex AE profiles — particularly immuno-oncology combinations — a dedicated safety review structure separate from the IDMC is sometimes warranted. This is particularly relevant when different arms have materially different safety profiles and when cross-arm safety signal assessment requires clinical judgment distinct from the adaptive efficacy decisions. Without a separate safety committee, safety assessments compete with efficacy review at IDMC meetings, and neither receives full attention.
Central IRB
Operationally, a central IRB is the operationally superior model for basket and umbrella trials (Sitero oncology program data). Local IRB review creates parallel review processes that cannot be synchronized across cohorts, prolonging activation and complicating amendment implementation. An AAHRPP-accredited central IRB operating under a master protocol provides consistent review standards and responsive amendment turnaround.
—
How Does Decision Authority Work in Practice?
Each governance body must have a documented charter specifying:
- What decisions it has authority to make independently
- What decisions require escalation to the steering committee
- What the timeline expectation is for each decision type
- How decisions are communicated to the operational team and sites
Without this specificity, decision delays default to the availability and bandwidth of whoever is informally expected to own the decision. In a multi-arm, multi-site program with frequent adaptation decisions, “informal ownership” is not a governance model — it is a delay accumulation mechanism.
Kyle Hanson, Director of Clinical Operations, Sitero:
“Sponsors coming from conventional parallel-arm trials are used to a single protocol, a single IND, and a single operations team. An umbrella trial requires a governance model most sponsors have never had to build: a master protocol committee with authority over cross-sub-study decisions; a process for adding, amending, and closing sub-studies without disrupting ongoing arms; clear rules for how IND safety reporting flows when sub-studies have different investigators; and a site contracting structure that can handle sub-study-level activation without requiring full re-initiation every time a new arm opens. The practical failure mode is that the sponsor runs the first sub-study competently, and then when sub-study two or three opens, they realize there’s no established process for how sites consent to the new arm, how RTSM gets updated, or who owns the safety integration. That’s when timelines collapse. The master protocol governance model needs to be designed at the outset, not reverse-engineered when the second sub-study is ready to open.”
—
Governance Design: Well-Structured vs. Poorly-Structured Programs
| Governance Element | Well-Structured Program | Poorly-Structured Program |
|---|---|---|
| Steering Committee | Charter with documented decision authority; multi-sponsor interest balancing explicit | Informal leadership structure; decision authority assumed, not documented |
| IDMC | Adaptive-experienced member; template interim reports pre-agreed; simulated interim completed | Standard DSMB setup; no adaptive design expertise required |
| Safety Review Committee | Separate from IDMC when arms have different safety profiles | Safety review merged with efficacy review at IDMC meetings |
| IRB model | Central IRB under master protocol (Sitero oncology program data) | Local IRB per cohort or hybrid with uncoordinated timelines |
| Amendment management | Defined process from IDMC recommendation → IRB → site notification; timeline documented | Ad hoc; amendment timeline depends on bandwidth of individuals involved |
| Communication protocols | Documented escalation paths; timeline commitments for each decision type | Informal; delays accumulate where ownership is unclear |
—
How Should Amendment Management Work Under a Master Protocol?
Basket and umbrella trials amend frequently — not because the protocol is poorly designed, but because the adaptive nature of the design generates protocol changes as part of normal operations. The governance structure must include an amendment management process that can move a protocol change from IDMC recommendation to IRB approval to site notification within a defined and predictable timeframe.
It is worth noting that the hybrid IRB approach — central IRB for most sites, local IRB retained for sites that do not permit central review — is operationally complex. “The local IRB process and associated committees can significantly prolong the time to trial activation” (Sitero oncology program data). The operational cost of hybrid governance is real and should be planned for, not discovered when the first amendment is due.
Three requirements for amendment management under a master protocol:
- A central IRB with experience in master protocol review and high-amendment-volume programs
- A documented amendment workflow with role assignments and timeline commitments from submission to site notification
- A tracking system that monitors amendment status across all IRB channels (central + local where hybrid) and escalates delays
—
5 Questions to Ask Your CRO About Master Trial Governance
- How do you design the steering committee charter for a multi-sponsor umbrella program — specifically, how is decision authority structured when sponsors have competing interests?
- What is your standard IDMC charter language for basket or umbrella trials, and does it include adaptive trial experience requirements?
- Do you have a relationship with an AAHRPP-accredited central IRB, and what is their standard amendment turnaround time for master protocol amendments?
- How do you manage the communication path from IDMC recommendation to steering committee decision to operational implementation — what is your documented timeline commitment?
- How do you handle sites that require local IRB review in a program structured around a central IRB?
Learn how Sitero manages basket and umbrella trial execution: Basket & Umbrella Trial Execution
Frequently Asked Questions
Q: How long does it typically take to activate a basket trial from protocol finalization to first patient screened?
Activation timelines for basket trials are longer than for single-indication studies because governance setup, central IRB review, and cohort-specific site feasibility must all be completed before first activation. Programs with pre-established central IRB relationships and a CRO experienced in master protocol governance can compress this timeline significantly. Programs that discover governance gaps during startup activation do not.
Q: How do you handle a situation where the IDMC recommends closing a cohort but the sponsor wants to continue?
The IDMC’s authority and the sponsor’s rights in response to IDMC recommendations must be explicitly documented in the IDMC charter before the trial starts. Most charters specify that the sponsor receives IDMC recommendations, has a defined period to respond, and can appeal to a defined body — but cannot unilaterally override a safety-based closure recommendation. The ambiguity that arises when these provisions are absent is legally and operationally problematic.
Q: What is the operational advantage of having the CRO also serve as the IRB in a basket or umbrella trial?
When the CRO and the IRB are the same organization, governance decisions and operational implementation are coordinated under one model, eliminating the hand-off delays between IRB decisions and operational implementation that typically slow complex oncology programs. Sitero’s AAHRPP-accredited IRB supports basket and umbrella trial governance through master protocol review, remote amendment management, and flexible committee operations designed for high-amendment-volume programs (Sitero oncology program data).
—
Planning an oncology trial with basket or umbrella trial governance requirements?
Sitero has supported 200+ oncology studies across 67+ countries. Talk to an oncology trial expert to discuss your protocol.
References
- Sitero. Oncology Program Operational Data. Internal dataset. 200+ oncology studies across 67+ countries. sitero.com/oncology/
- Hanson K. Director of Clinical Operations, Sitero. Expert interview conducted for this article. April 2026.
- Mossop, H., Walmsley, Z., Wilson, N. et al. Practical guidance for conducting high-quality and rapid interim analyses in adaptive clinical trials. BMC Med 23, 528 (2025). https://doi.org/10.1186/s12916-025-04362-x
Evaluating a CRO for a biomarker-driven oncology trial? Use these questions on site selection, central lab coordination, EDC design, and screening failure management.
In an adaptive oncology trial, the RTSM must do four things that a conventional randomization system is not required to do: enforce configurable cohort and dose assignment rules in real [...]
